Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus Inc. (NASDAQ: AGEN) announced the election of Paul Clark to its Board of Directors on August 31, 2020. Clark brings over 30 years of experience in the pharmaceutical and biotech industries, including leadership roles at ICOS and Abbott Laboratories. His expertise is expected to aid Agenus in transitioning to a commercial company as it prepares for the launch of its first immuno-oncology antibodies. Chairman and CEO Garo Armen highlighted Clark's valuable insights, anticipating positive impacts from his extensive experience in product development and commercialization.
Agenus Inc. (NASDAQ: AGEN) announced that data from two Phase 2 trials of balstilimab, both alone and in combination with zalifrelimab, will be presented at the European Society of Medical Oncology (ESMO) Conference on September 18, 2020. Dr. David O'Malley from Ohio State University will present the findings. The company remains on track to initiate a rolling Biologics License Application (BLA) submission for balstilimab monotherapy this quarter and aims to complete a data packet for the combination therapy by year-end.
Agenus Inc. (NASDAQ: AGEN) released its second quarter 2020 financial results, reporting a net loss of $48 million ($0.28 per share) compared to a loss of $52 million ($0.38 per share) in the same period last year. The company ended Q2 with a cash balance of $79 million, up from $62 million at the end of 2019. Agenus announced advancements in its clinical pipeline, including the initiation of the balstilimab BLA filing and promising results from its combo trials. For the first half of 2020, total revenue reached $42 million, down from $96 million in 2019.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, will present on Targeting Myeloid Cells in the Tumor Microenvironment at the William Blair Biotech Focus Conference 2020 on August 4, 2020, from 11:00 AM to 12:00 PM. The presentation aims to highlight innovative immuno-oncology strategies targeting the tumor microenvironment. Agenus, based in Lexington, MA, focuses on developing therapies to enhance immune responses against cancers and infections, utilizing advanced antibody and vaccine platforms.
Agenus Inc. (NASDAQ: AGEN) announced it will update its pipeline and financial results for Q2 2020 on August 6, 2020. The video conference call will review key topics including registration strategies for balstilimab and zalifrelimab, progress with Betta Pharmaceuticals in China, and the clinical advancement of AGEN1181. Additionally, the company will discuss breakthroughs in allogeneic iNKT cells for COVID-19 and cancer, along with updates on AGEN1223 and AGEN2373. The financial results will provide insight into the company’s fiscal health and future outlook.
Agenus Inc. (NASDAQ: AGEN) has secured a $20 million equity investment from Betta Pharmaceuticals, bringing total funding to $35 million. The investment is part of a broader immuno-oncology partnership, granting Betta exclusive rights for the development of Agenus' balstilimab and zalifrelimab in Greater China, with potential milestones of up to $100 million and royalties on net sales. Balstilimab is set for a BLA filing this year, having received Fast Track designation from the US FDA, positioning the company for significant growth.
Agenus (NASDAQ: AGEN), an immuno-oncology company, announced that Dr. Jennifer Buell and Dr. Manuel Hidalgo will discuss allogeneic iNKT cell therapy for infectious diseases at the B. Riley Virtual Infectious Disease Summit on July 21, 2020, from 3:00 PM to 4:00 PM ET. The panel, titled Pursuing Curative Cell Therapy Approaches, will feature AgenTus Therapeutics, a subsidiary of Agenus, alongside other biotech companies. The discussion will revolve around advancements in cell therapy, including AGENT-797, an early iNKT cell therapy aimed at enhancing the immune system's response to cancer.
Agenus Inc. (NASDAQ: AGEN) presented significant findings on its anti-CTLA-4 therapy, AGEN1181, during the AACR 2020 Virtual Annual Meeting. The therapy has exhibited promising clinical activity in early trials and demonstrated curative responses in preclinical models resistant to anti-PD-1. Dr. Antoine Tanne highlighted the potential of combining AGEN1181 with allogeneic cell therapies to enhance treatment effectiveness against solid tumors. The presentation aimed to expand the therapeutic use of immunotherapy in cancer treatment.
Agenus Inc. (NASDAQ: AGEN) announced a collaboration with Betta Pharmaceuticals for the exclusive development and commercialization of balstilimab and zalifrelimab in Greater China. The deal includes $35 million, consisting of $15 million in cash and a $20 million equity investment, along with up to $100 million in milestone payments and royalties on sales. Balstilimab has received Fast Track designation from the US FDA for cervical cancer treatment. Both companies aim to leverage their strengths to address significant patient needs in China.
Agenus Inc. (NASDAQ: AGEN) announced participation in the Raymond James Virtual Human Health Innovation Conference on June 17, 2020. Dr. Walter Flamenbaum, CEO of AgenTus Therapeutics, and Dr. Marc Van Dijk, CTO of Agenus, will discuss advancements in cell therapy from 12:00 PM to 12:50 PM ET. This panel will cover the evolution of cell therapy, particularly focusing on treatments for cancer, including new allogeneic therapies. Agenus aims to harness the immune system's power against cancer through innovative therapies and collaborations.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
